Cellectar Biosciences (CLRB) Environmental, Social & Governance (ESG) Data

The Company convened the Meeting at 10.00 a.m., local time, on June 24, 2022. The Meeting was held at the Executive Center on the first floor at 100 Campus Drive, Florham Park, New Jersey 07932, pursuant to notice duly given.

At the close of business on April 26, 2022, the record date for the determination of stockholders entitled to vote at the Meeting, there were 61,101,251 shares of the Company’s Common Stock, each share being entitled to vote, constituting all of the outstanding voting securities of the Company.

At the Meeting, the holders of 36,584,778 shares of the Company’s Common Stock were represented in person or by proxy, constituting a quorum.

Five proposals were presented for stockholder approval at the Meeting:

Proposal No.1 – Election of Directors

Class II directors, James V. Caruso and Frederick W. Driscoll, were nominated and elected to serve three-year terms. The vote was as follows:



Proposal No. 2 – Approval of an Increase in the 2021 Stock Incentive Plan Shares of 5,000,000

We requested approval of an increase in the number of shares of common stock available for issuance under the 2021 Stock Incentive Plan by 5,000,000 shares. The stockholders approved the increase. The vote was as follows:



Proposal No. 3 – Approval of Reverse Stock Split

We requested approval of an amendment to our Second Amended and Restated Certificate of Incorporation to effect a reverse stock split of our common stock at a ratio between 1:5 and 1:10, if and when determined by our Board of Directors. The stockholders approved the amendment. The vote was as follows:


Proposal No. 4 – Ratification of Appointment of Independent Registered Public Accounting Firm

We requested ratification of the appointment by the Audit Committee of our Board of Directors of Baker Tilly US, LLP to be our independent registered public accounting firm for fiscal year 2022. The stockholders ratified the appointment. The vote was as follows:


Proposal No. 5 – Approval of Executive Compensation

We requested approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers. The stockholders approved the compensation of the named executive officers. The vote was as follows: